What is PharmEnable?
PharmEnable is a United Kingdom-based drug discovery company that distinguishes itself through its focus on chemical novelty. Operating within the competitive pharmaceutical research and development sector, the company leverages its expertise to identify and develop novel therapeutic candidates. The company's strategic positioning suggests a commitment to innovation in addressing unmet medical needs.
How much funding has PharmEnable raised?
PharmEnable has raised a total of $9.9M across 2 funding rounds:
Angel/Seed
$2.4M
Other Financing Round
$7.5M
Angel/Seed (2020): $2.4M with participation from Cambridge Enterprise, David Ford, KQ Labs, Jonathan Milner, Andy Richards, o2h ventures, University of Cambridge Enterprise Fund VI, Martlet Capital, Wren Capital, Ian Tomlinson, and Paul Forster
Other Financing Round (2023): $7.5M led by MP Healthcare Venture Management
Key Investors in PharmEnable
Wren Capital
Wren Capital is an angel investor specializing in science, engineering, and software, founded in 2011 with over 60 investments. They focus on sectors such as software, semiconductors, medical devices, and others requiring technical ingenuity. Wren typically invests between £50,000 to £200,000 per funding round, emphasizing a pragmatic approach to deal-making.
MP Healthcare Venture Management
MP Healthcare Venture Management is a Boston-based life science venture capital firm that collaborates with healthcare entrepreneurs to develop novel technologies and therapeutics. The firm focuses on helping entrepreneurs build the life science companies of tomorrow. Their extensive network and deep expertise have been beneficial to their partners and clients.
Cambridge Enterprise
Cambridge Enterprise is the commercialization arm of the University of Cambridge, supporting academics in translating their research into successful businesses. They provide funding, expertise, and connections to help spin-outs and start-ups grow.
What's next for PharmEnable?
The substantial enterprise-level funding and recent strategic investment indicate PharmEnable is likely in a scaling phase, aiming to advance its drug pipeline through preclinical and clinical development. This capital infusion is expected to accelerate research initiatives, expand its scientific team, and potentially forge new strategic partnerships. The company's trajectory points towards significant growth and a push towards commercialization of its novel drug candidates.
See full PharmEnable company page
